In NSCLC, increasing PD-L1 expression levels on tumor cells generally are associated with response to immunotherapy.2,5 However, how to integrate TMB and PD-L1 expression to identify likely responders to ICI has been unclear. The gene discussed is CD274; the disease is non-small cell lung carcinoma.